Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Cancer treatment reviews - 1 Nov 2016

Calvo Emiliano, Schmidinger Manuela, Heng Daniel Y C, Grünwald Viktor, Escudier Bernard

Abstract excerpt

Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Everolimus
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Nivolumab

Share to Phenylurea Compounds

Share to Sorafenib

Share to Sunitinib

Source

Identifiers

PMID: 27664394
DOI: 10.1016/j.ctrv.2016.09.002

Genes

BAP1
PBRM1
SETD2
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.PMID 27664394Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

Molecular biomarkers in advanced renal cell carcinoma.Semantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic TherapiesSemantic proximity Read ↗

Renal cell carcinoma.Semantic proximity Read ↗

Prognostic models and algorithms in renal cell carcinoma.Semantic proximity Read ↗

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].Semantic proximity Read ↗

Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.Semantic proximity Read ↗

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.